Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

October 22nd 2025

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments

October 22nd 2025

Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

CAR2219 CAR T-Cell Therapy Yields Responses and a Manageable Safety Profile in R/R LBCL

October 21st 2025

CAR2219 induced high response rates in relapsed/refractory LBCL, and the role of post-infusion maintenance therapy is worthy of further study.

Liso-Cel Data Confirm Durable Efficacy and Confer Broad Use in R/R LBCL

October 21st 2025

Taylor Brooks, MD, discusses data that supported the FDA approvals of liso-cel across LBCL treatment settings and details of the agent’s toxicity profile.

Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis

October 21st 2025

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Dr Mouhieddine on Clinical Implications of Ferritin and ALC as Biomarkers in Myeloma

October 21st 2025

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

Dr Lee on the Optimal Patient Population to Receive Proton Therapy for Advanced NSCLC

October 21st 2025

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

BTK Inhibitors, CAR T-Cell Therapies, and JAK Inhibitors Refine Hematologic Oncology Standards

October 21st 2025

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

Metastatic Breast Cancer 2025 UPDATE

October 20th 2025

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer

October 20th 2025

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.

Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer

October 20th 2025

Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.

FDA Awards Breakthrough Therapy Designation to Bezuclastinib for Non-Advanced Systemic Mastocytosis

October 20th 2025

Bezuclastinib received breakthrough therapy designation for pretreated non-advanced systemic mastocytosis, as well as for smoldering systemic mastocytosis.

FDA Accepts BLA Resubmission for RP1 Plus Nivolumab in Advanced Melanoma

October 20th 2025

Will the FDA approve a resubmitted biologics license application for RP1 plus nivolumab in advanced melanoma after progression on anti–PD-1 therapy?

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC

October 19th 2025

Tislelizumab plus induction chemotherapy and concurrent chemoradiation demonstrated efficacy worthy of further study in locally advanced ESCC.

Chemotherapy Plus Durvalumab, Bevacizumab, and Olaparib Fails to Offer OS Benefit in Newly Diagnosed Non-tBRCA–Mutated Ovarian Cancer

October 19th 2025

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC

October 19th 2025

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC

October 18th 2025

Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma

October 18th 2025

Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease

October 18th 2025

T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.

Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

October 17th 2025

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

NEXT PAGE
PREVIOUS PAGE